ACTG has launched A5374, a Phase I/IIa clinical trial to evaluate the safety, tolerability, and antiviral effect of a ...

head of the HIV Prevention Trials Network says there are four areas of research which are being investigated in HIV; ...

The start of AIDS Awareness Month puts a spotlight on how treatment for HIV and AIDS has progressed over the past 40 years.

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Dolutegravir is an HIV integrase ... with few treatment discontinuations due to adverse effects. Headache, nausea and diarrhea were the most likely side effects reported in clinical trials.

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

DRIVE-AHEAD included 728 patients not previously treated for HIV who were ... After 48 weeks of treatment, viral suppression rates were comparable between the two study groups, indicating that ...

Blog - allAfrica's Sethi Ncube is in Lima, Peru, for the 5th HIV Research for Prevention Conference, HIVR4P 2024, reporting ...

they plan to study how it performs when given in conjunction with both antibiotics and cART together. This treatment regimen is standard for patients with both HIV and active TB. Dr. Mehra said ...

As we advance through 2024, significant updates in Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infections (STI) prevention and treatment are emerging. Recent clinical trials and global ...

Sweden has reached the UNAIDS and WHO targets for the HIV epidemic, according to a study in Eurosurveillance by researchers ...

However, most people living with HIV in the U.S. do not develop AIDS, because effective treatment options are available. Today, when utilizing effective treatment, people with HIV can live long ...